Inappropriate Medications and Alzheimer Disease: Prevalence and Associated Factors in Elderly Patients Treated With Anticholinesterase and/or Memantine. MIDA Study.
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 636
- 试验地点
- 6
- 主要终点
- To evaluate the prevalence of PIM use in patients aged 75 years and over treated with anticholinesterase and/or memantine
研究概览
简要总结
In each of the 7 French areas that should be involved, patients aged 75 years and over from three different sectors will be included: the geriatric consultation unit (60%) and two kinds of nursing homes, private (20%) and state (10%). Outpatients will be included in chronological order; patients in nursing homes will be included at random. The patients and their families will be asked about the treatments received on the day of inclusion. The inclusion period will extend over a year. The investigating practitioners will be asked to fill in a questionnaire reporting the main clinical data, adverse effects occurrence, and information on the treatment given.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 75 Years 至 —（Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients aged 75 years and over identified as having Alzheimer disease and who have been treated for more than 3 months with anticholinesterase and/or memantine
排除标准
- •Patients with decompensated chronic condition or acute phase disease
结局指标
主要结局
To evaluate the prevalence of PIM use in patients aged 75 years and over treated with anticholinesterase and/or memantine
时间窗: 2 years
次要结局
- To identify factors associated with PIM use. To study the relationship between PIM exposure and adverse effects occurrence.(2 years)